Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose versus iron sucrose in haemodialysis patients with iron deficiency anaemia
ISRCTN87502816Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- Jul 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose and iron sucrose in iron deficiency anemia (IDA), sponsored by CSL Vifor. Primary endpoint: Haemoglobin response at 4 weeks. Started Jul 2004; status: completed.
02
Drugs
ferric carboxymaltoseiron sucrose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ISRCTN87502816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN87502816.